Hormonal therapy continues to be the treatment of initially option for metastatic individuals with endocrine-responsive breast cancer (LoE 1a A, In the past ++). The sequential use from the out there medicine relies on the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue